Conduction of pre-clinical and clinical tests to produce of humanized monoclonal antibody (Biopharmaceutical).

Recepta Antibodies

From the laboratory to the patient

Monoclonal antibody RebmAb700/AGEN2034

Monoclonal antibody RebmAb700/AGEN2034

Antibody generated through a partnership between ReceptaBio, LCR and the company 4-Antibody (which was later acquired by Agenus Inc.). It is a human monoclonal antibody to block the programmed death 1 (PD-1) cell protein, an important negative regulator (suppressor) of T lymphocyte responses. By blocking PD-1, the immune response is increased through the inhibition of negative regulation of T lymphocytes activation, consequently increasing the antitumor immune response. Using data from the Phase I clinical studies, being conducted in the United States (NCT03104699), the dose for an ongoing Phase II clinical study on cervical cancer was defined. This molecule is also in a Phase I clinical study in combination with RebmAb600/AGEN1884 (NCT03495882). By acting increasing the response of the immune system to the tumor, studies are planned in several therapeutic indications for RebmAb700.

Monoclonal antibody RebmAb600/AGEN1884

Monoclonal antibody RebmAb600/AGEN1884

Like RebmAb700/AGEN2034, this antibody was also generated through a partnership between ReceptaBio, LCR and the company 4-Antibody (which was later acquired by Agenus Inc.). It is a human monoclonal antibody that blocks the antigen 4 associated with the cytotoxic T lymphocyte (CTLA-4), an important negative regulator (suppressor) of the T lymphocyte responses. By blocking CTLA-4, the immune response increases through inhibition of the negative regulation of T lymphocyte activation, consequently stimulating the antitumor immune response. This molecule is in a Phase I clinical study in the United States (NCT02694822), and also in a Phase I clinical study in combination with RebmAb700/AGEN2034 (NCT03495882).

Monoclonal antibody RebmAb200

Monoclonal antibody RebmAb200

The humanization of murine anti-NaPi2b antibody and the generation of a stable cell line for the production of the humanized antibody RebmAb200 was a pioneering work in Brazil conducted by ReceptaBio. RebmAb200 target expression, NaPi2b, a phosphate carrier protein found in the cell membrane, was evaluated by ReceptaBio collaborating researchers and its high expression in breast, lung and ovary tumors, associated with high specificity, efficiency and sensitivity of the antibody, has been found. In July 2015, RebmAb200 was licensed to Mersana Therapeutics, an American biopharmaceutical company that has state-of-art technology for the production of ADCs (antibody-drug conjugates). This was the first intellectual property of a drug licensed by Brazil. Pre-clinical tests using RebmAb200 with ADC technology from Mersana Inc., - which received an award for the best ADCs technology platform in 2016 - showed great anti-tumor activity in animal models, confirming its potential as a new biopharmaceutical drug. This ADC - called by Mersana XMT-1536 - is under First-in-Human Phase Ib clinical study (NCT03319628), in the USA.

Monoclonal antibody RebmAb100

Monoclonal antibody RebmAb100

The humanized monoclonal antibody RebmAb100 recognizes the Y antigen of the Lewis blood group (LeY). LeY has a pronounced expression in tumor tissues, especially in epithelial carcinomas, when compared to its expression in non-tumor tissues. LeY antigen is considered a tumor target with important potential in diagnosis and treatment. Immuno-histochemical studies, preclinical studies, and Phase I clinical tests were conducted with RebmAb100 by LCR researchers and their results justified the continuation of clinical trials aiming to determine their therapeutic efficacy. ReceptaBio has conducted Phase II clinical trials in Brazil in patients with ovarian (NCT01137071, NCT00617773) and breast (NCT01370239) tumor.

Monoclonal antibody RebmAb300

Monoclonal antibody RebmAb300

It is a monoclonal antibody that recognizes Lewis blood group B antigen (LeB). As observed for LeY, LeB expression is increased in several types of carcinomas of epithelial origin, such as colorectal, lung, ovary and breast, among others. Notably, elevated LeB expression is correlated with less favorable prognoses of these carcinomas, indicating favorable perspectives for therapeutic use of the antibody in different neoplasms.

Monoclonal antibody RebmAb400

Monoclonal antibody RebmAb400

The antibody recognizes antigen A34, a glycoprotein belonging to the family of adherent junction molecules. Its expression is particularly high in gastric and esophageal adenocarcinomas. More comprehensive assessment of possible therapeutic uses for RebmAb400 has been carried out in order to better define the development of this monoclonal antibody.

Top